Indaptus Therapeutics (INDP) to Announce Earnings on Monday

Indaptus Therapeutics (NASDAQ:INDP) is expected to be releasing its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect Indaptus Therapeutics to post earnings of ($1.57) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64.

Indaptus Therapeutics Stock Performance

Shares of INDP opened at $1.18 on Monday. The business has a 50-day moving average of $2.70 and a 200 day moving average of $2.27. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $8.69. The firm has a market cap of $133.62 million, a P/E ratio of -0.08 and a beta of 1.18.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on INDP shares. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.